Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Access to critical medicines: When are compulsory licenses effective in price negotiations?
Shyama V. Ramani, Eduardo Urias
Social Science & Medicine (2015) Vol. 135, pp. 75-83
Closed Access | Times Cited: 21

Showing 21 citing articles:

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
Swathi Iyengar, Kiu Tay-Teo, Sabine Vogler, et al.
PLoS Medicine (2016) Vol. 13, Iss. 5, pp. e1002032-e1002032
Open Access | Times Cited: 231
Pathways to ensure universal and affordable access to hepatitis C treatment
Caitlin Douglass, Alisa Pedrana, Jeffrey V. Lazarus, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 65
Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence
Eduardo Urias, Shyama V. Ramani
Journal of International Business Policy (2020) Vol. 3, Iss. 4, pp. 367-384
Open Access | Times Cited: 42
Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines
Kyung‐Bok Son, Tae-Jin Lee
Global Public Health (2017) Vol. 13, Iss. 10, pp. 1430-1440
Closed Access | Times Cited: 37
Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis
Kyung‐Bok Son
Globalization and Health (2019) Vol. 15, Iss. 1
Open Access | Times Cited: 28
Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries
Joel W Sim, Andrew Hill
Journal of Virus Eradication (2018) Vol. 4, Iss. 4, pp. 230-237
Open Access | Times Cited: 16
Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies
Archita Sarmah, Domenico De Giovanni, Pietro De Giovanni
European Journal of Operational Research (2019) Vol. 282, Iss. 3, pp. 1053-1069
Open Access | Times Cited: 15
High-value hi-tech product introduction in emerging countries
Shyama V. Ramani, Ajay Thutupalli, Eduardo Urias
Qualitative Market Research An International Journal (2017) Vol. 20, Iss. 2, pp. 208-225
Open Access | Times Cited: 13
When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil
Shyama V. Ramani, Eduardo Urias
Research Policy (2018) Vol. 47, Iss. 8, pp. 1538-1552
Open Access | Times Cited: 12
The contribution of the Pharmaceutical Industry to the health status of the developing world
Eduardo Urias
International business and management series (2017), pp. 41-67
Open Access | Times Cited: 11
Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: A realist synthesis
Kyung‐Bok Son, Chang‐Yup Kim, Tae-Jin Lee
Global Public Health (2018) Vol. 14, Iss. 1, pp. 122-134
Closed Access | Times Cited: 7
Actores, relaciones estructurales y causalidad en la innovación inclusiva: un caso de telemedicina en México
Nayeli Velázquez, Gabriela Dutrénit, Natàlia Gras, et al.
Innovar (2018) Vol. 28, Iss. 70, pp. 23-38
Open Access | Times Cited: 7
Positioning and negotiations: The case of pharmaceutical pricing
Sverre Grepperud, Pål Andreas Pedersen
European Journal of Political Economy (2020) Vol. 62, pp. 101853-101853
Open Access | Times Cited: 7
Determinants of innovative social entrepreneurship
Nayeli Velázquez, Gabriela Dutrénit
Revista Brasileira de Inovação (2019) Vol. 18, Iss. 2, pp. 223-248
Open Access | Times Cited: 6
Propriedade intelectual do soro antiofídico: a efetividade a partir da correlação entre os investimentos do governo federal nos principais institutos responsáveis pela produção do soro e realização de pesquisas para o tratamento de acidentes ofídicos no brasil, com relação ao número de vítimas fatais dos acidentes
Vitor Hugo da Silva Vaz, Osiris Ashton Vital Brazil, Ana Eleonora Almeida Paixão
Cadernos Saúde Coletiva (2020) Vol. 28, Iss. 3, pp. 409-421
Open Access | Times Cited: 5
A method for understanding generic procurement of HIV medicines by developing countries with patent protection
Reed F. Beall, Amir Attaran
Social Science & Medicine (2017) Vol. 185, pp. 118-126
Closed Access | Times Cited: 3
Compulsory license threats in a signaling game of drug procurement
Damien Besancenot, Samira Guennif
Theory and Decision (2024) Vol. 97, Iss. 2, pp. 261-298
Closed Access
Country versus pharmaceutical company interests for hepatitis C treatment
Roy Lothan, Noa Gutman, Dan Yamin
Health Care Management Science (2022) Vol. 25, Iss. 4, pp. 725-749
Open Access | Times Cited: 2
Impact of TRIPS on Providing Easy Access to Affordable Medicines in India
Shalini Arora, Rekha Chaturvedi
(2017)
Closed Access | Times Cited: 1
How Much Time Before Attempting Compulsory Licensing of Pharmaceuticals? A Non-parametric Event History Model With P-splines
Kyung‐Bok Son
International Journal of Health Services (2018) Vol. 49, Iss. 1, pp. 68-84
Closed Access
SOFOSBUVIR: TREATMENT OF CHRONIC HEPATITIS C AND THE MAIN TRENDS IN PATENT PROTECTION
Olena Litvinova, Olga Posilkina, MASLOVA NATALIIA F.
International Journal of Applied Pharmaceutics (2019), pp. 8-14
Open Access
Page 1

Scroll to top